Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Ozempic can even cut risk of Alzheimer’s disease, study says
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in diabetes patients.
Ozempic could help reduce Alzheimer’s risk for some, study suggests: ‘Shifting the paradigm’
Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of Alzheimer’s disease for certain groups, a new study finds.
Ozempic linked to lower Alzheimer's risk in people with Type 2 diabetes
Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.
2h
on MSN
Diabetes patients worry about insulin shortages as Ozempic use skyrockets
The 62-year-old administrative law judge has Type 1 diabetes and needs the medication to live. The pharmacist ...
The Economist
13h
GLP-1s like Ozempic are among the most important drug breakthroughs ever
The brain has GLP -1 receptors in abundance and, though very little drug seems to be able to cross the blood-brain barrier ...
4h
Ozempic May Be Linked to Lower Risk of Alzheimer’s in People with Type 2 Diabetes
Published in Alzheimer’s & Dementia on Thursday, Oct. 24, the study found that semaglutide — the active ingredient in popular ...
2h
on MSN
As insulin shortages persist, what diabetes patients can do
Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Alzheimer's disease
Food and Drug Administration
Novo Nordisk
Wegovy
Semaglutide
Feedback